Dr. Srilaxmi Gujjula, MD

Dr. Gujjula practices at Cooper University Hospital Cape Regional in Cape May Court House, New Jersey, part of Cooper University Health Care.

Dr. Gujjula's NPI, 1750876553, was assigned on June 25, 2018. Dr. Gujjula holds New Jersey license 25MA12064200.

Dr. Gujjula's primary practice is Cooper University Hospital Cape Regional, at Two Stone Harbor Blvd, Cape May Court House, NJ 08210 in Cape May County. The practice phone is (609) 463-2000. Dr. Gujjula also practices at Cooper University Hospital Cape Regional, 2 Stone Harbor Blvd, Cape May Court House, NJ 08210.

Dr. Gujjula's primary practice is Cooper University Hospital Cape Regional in Cape May Court House, New Jersey, part of Cooper University Health Care. Dr. Gujjula is also affiliated with Cooper University Hospital. The medical group on file is Cooper University Physicians. Dmand AI also links Dr. Gujjula to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gujjula practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Gujjula's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Gujjula is licensed in New Jersey.

CMS data shows 49 Medicare services from Dr. Gujjula across 3 procedure codes in 2024, for 69 Medicare patients. Medicare paid $3,724 for them.

CMS counts 69 Medicare patients who saw Dr. Gujjula in 2024. The largest group is 65 to 74, with 31 patients. 75% of them have high cholesterol, and 72% have high blood pressure. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Gujjula's median patient age at 68, with 72% women.

In 2024, Dr. Gujjula wrote 99 Medicare Part D claims for 65 patients. 89% of them were for generic drugs. CMS names the drug for 45 of them, across 2 drugs with 11 or more claims each, at $680 in total drug cost. In 2023, CMS named 71 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Gujjula for performance year 2024, reported as part of a group. Dr. Gujjula accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 66 procedures of colonoscopy by Dr. Gujjula, more than 70% of the clinicians it reports for that procedure.

Dmand AI links 2 papers to Dr. Gujjula in 2019. 2019 was the busiest year, with 2. Dr. Gujjula has published most often in Cureus. Dr. Gujjula's most frequent co-author is Mel Angelo Ona, MA, MD, MPH, MS.

CMS Open Payments shows 16 general payments to Dr. Gujjula from 8 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 95% of the total. Abbvie Inc. paid the most, $277.